title: Viral load and ganciclovir (GCV) concentration in cerebrospinal fluid of patients successfully treated with GCV or valGCV for human herpesvirus 6 encephalitis/myelitis following umbilical cord blood transplantation.
abstract: We describe successful treatment of 3 cases of human herpesvirus 6 (HHV-6) encephalitis/myelitis following cord blood transplantation (CBT). Ganciclovir (GCV) (10 mg/kg/day) reduced HHV-6 load to undetectable levels in cerebrospinal fluid (CSF). Early dose reduction in the presence of HHV-6 detectable in CSF resulted in an increased HHV-6 load. GCV was capably shifted to valganciclovir (VGCV) with an almost equivalent concentration. GCV/VGCV may be effective for HHV-6 encephalitis/myelitis after CBT, although HHV-6 load in CSF should be monitored.
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Morita
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hirabayashi
authors.affiliation: Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Katsuyama
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Morokawa
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Motobayashi
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kurata
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shigemura
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Inaba
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Koike
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. yxnakaza@shinshu-u.ac.jp.
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazawa
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002675:Child, Preschool; D004279:DNA, Viral; D018792:Encephalitis, Viral / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D005260:Female; D005312:Fetal Blood; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D015654:Herpesvirus 6, Human / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D009187:Myelitis / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D019653:Myeloablative Agonists / Q000009:adverse effects; D019349:Roseolovirus Infections / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000821:virology; D019172:Transplantation Conditioning / Q000009:adverse effects*; D016896:Treatment Outcome; D000077562:Valganciclovir; D019562:Viral Load / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019653:Myeloablative Agonists; D000077562:Valganciclovir; D015774:Ganciclovir
keywords: HHV-6; cerebrospinal fluid; cord blood transplantation; encephalitis; ganciclovir; valganciclovir